Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Down 41.0% in May

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the target of a large drop in short interest during the month of May. As of May 29th, there was short interest totaling 175,238 shares, a drop of 41.0% from the May 14th total of 296,872 shares. Based on an average daily volume of 292,130 shares, the short-interest ratio is currently 0.6 days. Currently, 1.1% of the shares of the company are short sold.

Allarity Therapeutics Price Performance

Allarity Therapeutics stock traded up $0.05 during trading hours on Monday, hitting $1.48. The company had a trading volume of 46,008 shares, compared to its average volume of 185,097. Allarity Therapeutics has a one year low of $0.77 and a one year high of $2.35. The firm has a 50-day moving average of $1.45 and a 200 day moving average of $1.21. The firm has a market cap of $23.55 million, a PE ratio of -2.06 and a beta of 0.52.

Allarity Therapeutics (NASDAQ:ALLR) last announced its earnings results on Friday, May 15th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.05. The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.03 million. As a group, research analysts expect that Allarity Therapeutics will post -0.92 earnings per share for the current year.

Institutional Trading of Allarity Therapeutics

Several large investors have recently made changes to their positions in the company. Private Advisor Group LLC acquired a new stake in shares of Allarity Therapeutics during the 3rd quarter worth approximately $441,000. Renaissance Technologies LLC boosted its position in shares of Allarity Therapeutics by 274.1% during the 4th quarter. Renaissance Technologies LLC now owns 247,612 shares of the company’s stock worth $267,000 after acquiring an additional 181,426 shares in the last quarter. DRW Securities LLC acquired a new stake in shares of Allarity Therapeutics during the 4th quarter worth approximately $133,000. Capital Advisors Inc. OK acquired a new stake in shares of Allarity Therapeutics during the 4th quarter worth approximately $108,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Allarity Therapeutics during the 3rd quarter worth approximately $149,000. Institutional investors and hedge funds own 11.53% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Allarity Therapeutics in a research note on Monday, April 20th. Ascendiant Capital Markets raised their target price on shares of Allarity Therapeutics from $9.75 to $10.25 and gave the company a “buy” rating in a research note on Monday, June 8th. Finally, Wall Street Zen upgraded shares of Allarity Therapeutics to a “hold” rating in a research note on Saturday, May 30th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Allarity Therapeutics currently has an average rating of “Hold” and a consensus price target of $10.25.

Allarity Therapeutics Company Profile

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.